Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Gskb Pharmaceuticals LLC currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are spread across 2 distinct art units, suggesting that the company's pharmaceutical research touches on multiple specialized technical fields. Despite the multiple art units, the company is only dealing with a single distinct examiner for both matters, which is a concentration that may simplify the overall prosecution strategy.
RAMOS LEWIS, JOSMALEN MILAGROS is the busiest examiner, managing 2 pending office actions. Because the busiest examiner pending count accounts for all of the company's pending actions, the prosecution strategy is highly centralized. This examiner's influence is significant across the company's Biotechnology & Pharmaceuticals portfolio, as they are the sole individual reviewing the current pending applications across different art units. This situation allows the applicant to apply consistent arguments and terminology across both pending matters, potentially leading to a more uniform patent portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAMOS LEWIS, JOSMALEN MILAGROS | 2 | 53.6% | +23.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18633291 | COMBINATION THERAPY FOR THE TREATMENT OF PSYCHIATRIC DISORDER | RAMOS LEWIS, JOSMALEN MILAGROS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19067074 | COMBINATION THERAPY FOR THE TREATMENT OF PSYCHIATRIC DISORDER | RAMOS LEWIS, JOSMALEN MILAGROS | 34d |
| 18633291 | COMBINATION THERAPY FOR THE TREATMENT OF PSYCHIATRIC DISORDER | RAMOS LEWIS, JOSMALEN MILAGROS | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 4100 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19067074 | COMBINATION THERAPY FOR THE TREATMENT OF PSYCHIATRIC DISORDER | RAMOS LEWIS, JOSMALEN MILAGROS | 1621 | §103 | Non-Final OA | 34d | Pending | Feb 28, 2025 |
| 18633291 | COMBINATION THERAPY FOR THE TREATMENT OF PSYCHIATRIC DISORDER | RAMOS LEWIS, JOSMALEN MILAGROS | 4100 | §103§112 | Non-Final OA | — | Pending | Apr 11, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial